KalVista Pharmaceuticals (NASDAQ:KALV) Given New $28.00 Price Target at Citizens Jmp

KalVista Pharmaceuticals (NASDAQ:KALV) had its price objective lowered by Citizens Jmp from $29.00 to $28.00 in a research report released on Thursday morning,Benzinga reports. The firm currently has a market outperform rating on the specialty pharmaceutical company’s stock.

A number of other analysts have also recently weighed in on the stock. Needham & Company LLC raised their price objective on shares of KalVista Pharmaceuticals from $35.00 to $36.00 and gave the stock a “buy” rating in a report on Wednesday. HC Wainwright upped their target price on shares of KalVista Pharmaceuticals from $27.00 to $37.00 and gave the company a “buy” rating in a report on Friday, January 9th. TD Cowen reaffirmed a “buy” rating on shares of KalVista Pharmaceuticals in a research report on Wednesday, December 3rd. Wall Street Zen upgraded shares of KalVista Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, December 6th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of KalVista Pharmaceuticals in a research report on Thursday, January 22nd. Seven investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $32.60.

KalVista Pharmaceuticals Price Performance

KALV stock opened at $18.95 on Thursday. The business has a 50 day moving average price of $15.95 and a 200 day moving average price of $14.44. The company has a quick ratio of 7.21, a current ratio of 7.22 and a debt-to-equity ratio of 8.18. The stock has a market cap of $957.92 million, a price-to-earnings ratio of -4.80 and a beta of -0.35. KalVista Pharmaceuticals has a fifty-two week low of $9.23 and a fifty-two week high of $19.27.

Insider Buying and Selling at KalVista Pharmaceuticals

In related news, insider Paul K. Audhya sold 5,354 shares of the stock in a transaction on Monday, February 23rd. The shares were sold at an average price of $15.57, for a total transaction of $83,361.78. Following the completion of the sale, the insider owned 138,983 shares in the company, valued at $2,163,965.31. This represents a 3.71% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Brian Piekos sold 1,767 shares of the firm’s stock in a transaction on Monday, February 23rd. The stock was sold at an average price of $15.57, for a total transaction of $27,512.19. Following the transaction, the chief financial officer directly owned 13,762 shares in the company, valued at $214,274.34. The trade was a 11.38% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 33,378 shares of company stock valued at $522,290. 4.30% of the stock is currently owned by insiders.

Institutional Investors Weigh In On KalVista Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Seven Fleet Capital Management LP purchased a new stake in shares of KalVista Pharmaceuticals in the fourth quarter valued at about $782,000. Invesco Ltd. grew its holdings in shares of KalVista Pharmaceuticals by 23.1% during the fourth quarter. Invesco Ltd. now owns 77,864 shares of the specialty pharmaceutical company’s stock worth $1,258,000 after buying an additional 14,621 shares during the last quarter. XTX Topco Ltd purchased a new position in shares of KalVista Pharmaceuticals during the fourth quarter worth about $428,000. Vestal Point Capital LP increased its position in KalVista Pharmaceuticals by 152.0% in the 4th quarter. Vestal Point Capital LP now owns 1,890,000 shares of the specialty pharmaceutical company’s stock valued at $30,524,000 after acquiring an additional 1,140,000 shares during the period. Finally, Virtus Investment Advisers LLC increased its position in KalVista Pharmaceuticals by 364.9% in the 4th quarter. Virtus Investment Advisers LLC now owns 40,414 shares of the specialty pharmaceutical company’s stock valued at $653,000 after acquiring an additional 31,721 shares during the period.

Trending Headlines about KalVista Pharmaceuticals

Here are the key news stories impacting KalVista Pharmaceuticals this week:

• Positive Sentiment: Company reported $49.1M in EKTERLY revenue during an eight‑month transition period and highlighted a strong launch that supports topline growth expectations. KalVista posts $49.1 million in EKTERLY revenue
• Positive Sentiment: Corporate update and eight‑month FY2025 results emphasized commercial progress and operational updates that underpin near‑term revenue visibility. KalVista Reports Eight Months Fiscal Year 2025 Financial Results and Provides Corporate Update
• Positive Sentiment: Stifel Nicolaus raised its price target to $42 and kept a “buy” rating — implying ~122% upside from the current price — reflecting bullish analyst views on commercial execution and upside potential. Stifel raises KALV price target
• Positive Sentiment: Needham & Company increased its target from $35 to $36 and maintained a “buy” rating, signaling continued analyst confidence in EKTERLY’s market opportunity. Needham raises KALV price target
• Neutral Sentiment: Q1/8‑month earnings call transcripts (and related highlights) are available; these provide detail on revenue cadence, channel dynamics, and management commentary that investors should review for execution risk and guidance clarity. Q1 2025 earnings call transcript 8 Months 2025 earnings call transcript
• Negative Sentiment: Citizens Jmp trimmed its price target from $29 to $28 and moved to “market outperform” — a mild downgrade in target that could temper enthusiasm despite still-significant upside (~48%). Citizens Jmp lowers KALV price target

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.